Weight Watchers Beats 2025 Guidance as GLP-1 Clinical Subscribers Jump 42%
WW International reported Q4 and full-year 2025 results beating guidance, with strong growth in clinical subscribers thanks to GLP-1 integration.
/ 894 items
#Healthcare↓
Jefferies Slaps Buy Rating on Cogent Biosciences as FDA Accepts Bezuclastinib NDA for Non-Advanced Systemic Mastocytosis
Jefferies analyst started coverage on Cogent Biosciences with a Buy rating and $55 price target after the FDA accepted the NDA for bezuclastinib in Non-Advanced Systemic Mastocytosis. PDUFA date set for December 30, 2026.
Structure Therapeutics' Oral Obesity Pill Aleniglipron Hits Record 16.3% Weight Loss in Phase 2 Trial – Matches Injectables with No Plateau
Structure Therapeutics' oral pill aleniglipron achieved 15–16% body weight loss (up to 39 lbs) after 44 weeks in Phase 2, rivaling injectables with better tolerability and no plateau. Phase 3 is planned for 2026—a potential game changer for obesity treatment.
BTIG Initiates Buy on Zevra After $50M Portfolio Sale and Debt-Free Move
BTIG starts coverage on ZVRA with Buy rating and $23 target after Zevra sells SDX portfolio for $50 million and becomes debt-free.
Abivax Gets a $160 Boost: Jefferies Sees 'Differentiated' Obefazimod as UC Game-Changer
Jefferies starts Abivax coverage with Buy rating and $160 target. Views obefazimod as differentiated UC therapy; Q2 maintenance data de-risked for approval path.
ImmunityBio Builds the “World Bank of NK Cells”: 5 Billion Cancer-Fighting Cells from One Blood Draw in Just 12 Days
ImmunityBio just hit a huge milestone – they can now mass-produce and freeze powerful NK cells from healthy and cancer donors. One simple blood draw gives 8–10 ready-to-use doses.